Compare Citius Pharmaceuticals Inc (CTXR) vs Futu Holdings Ltd (FUTU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Futu Holdings Ltd — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Futu Holdings Ltd trades at $113.71 (market cap $15.25B). The key difference: Futu Holdings Ltd is far larger — about 1119.7× Citius Pharmaceuticals Inc's market cap, and Futu Holdings Ltd pays a 2.39% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Futu Holdings Ltd for 34 Days on average.
| CTXR | FUTU | |
|---|---|---|
Market Cap | $13.62M | $15.25B |
Volume | 132,438 | 812,567 |
Sector | Health | Financials |
52-Week High | $1.82 | $199.04 |
52-Week Low | $0.48 | $89.76 |
Typical Hold Time | 17 Days | 34 Days |
Enterprise Value | $3.79M | $15.59B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4994, down 1.73% with a bearish technical signal despite oscillators showing oversold conditions. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR commercial sales, but continues to post significant losses with a -651.27% net income margin. Recent news highlights strong commercial momentum for LYMPHIR with 44 institutions ordering the treatment since launch.
The stock presents a high-risk opportunity with analyst consensus strongly bullish (83% buy ratings, $5 price target) but fundamental challenges persist. Key risks include ongoing cash burn and execution of commercial strategy, while potential upside depends on successful LYMPHIR adoption and path to profitability.
FUTU trades at $113.71, up 3.67% today, with a bearish technical signal but strong fundamentals including a 10.86 P/E ratio and 42.92% net margin. Revenue grew to $22.85B in 2025, and cash flow surged to $31.02B in 2024. Recent news highlights expansion efforts like the Moomoo X partnership and a class action lawsuit deadline.
The outlook is mixed: analysts see a 33.7% upside (Zacks, 2026-09-10), but technicals and legal risks weigh. Investment opportunity lies in valuation and growth; risks include lawsuit uncertainty and competitive pressures. Earnings beat in Q2 2026 supports momentum, but Q1 2026 miss shows volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Futu Holdings Ltd
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Read more on FUTU →
